Coherus Oncology, Inc.

Coherus Oncology, Inc. is a U.S.-based commercial-stage oncology company focused on proprietary immuno-oncology medicines. Its core business is the commercialization of LOQTORZI (toripalimab-tpzi) and the advancement of mid-stage pipeline candidates aimed at overcoming immune resistance in cancer.

−426,4 %

67,2 %

398,4 %

+59,8 %

1.47

1.45

— Coherus Oncology, Inc.
%
Commercial oncology product70% Approved immuno-oncology therapy sold in the United States and supported by partner commercialization in Canada.
Clinical-stage pipeline20% Mid-stage and early-stage oncology candidates being developed for additional cancer indications and combinations.
Licensing and collaboration rights10% Exclusive regional rights, options, and milestone/royalty arrangements tied to toripalimab and related assets.

The company sells primarily into the oncology treatment ecosystem, where prescribing physicians, hospitals, integrated...

  • Oncology prescribersprimary

    Medical oncologists and treatment centers that prescribe LOQTORZI based on efficacy, safety, and label fit.

  • Hospitals and cancer networksprimary

    Hospitals, integrated delivery networks, and cancer centers that decide formulary inclusion and treatment pathways.

  • Payers and reimbursement gatekeepersprimary

    Government and commercial payers that determine coverage and patient access for oncology biologics.

  • Strategic partnerssecondary

    License and collaboration partners that help commercialize or develop assets in selected territories.

Coherus Oncology primarily operates in the United States and measures its business as one reportable segment centered...

  • •United States is the core commercial and operating market
  • •Canada is addressed through a licensing/partner model
  • •Other countries are served mainly through partners, not direct ops
  • •Biomanufacturing is being onshored to the United States
  • •U.S. concentration increases exposure to domestic pricing and reimbursement

The company’s strategy is to build LOQTORZI sales in nasopharyngeal carcinoma while expanding into new indications and...

01
Expand LOQTORZI commercializationshort-term

The approved product is the main revenue engine and the base for future indication expansion.

02
Advance pipeline candidatesmedium-term

Pipeline success is needed to diversify revenue and support long-term growth beyond one marketed product.

03
Strengthen manufacturing controlmedium-term

Reducing dependence on third-party CMOs can improve supply security and commercial readiness.

The business is highly dependent on a single approved product and on successful clinical, regulatory, and commercial...

high

Dependence on LOQTORZI

The company has only one approved commercial product, so any launch, safety, or reimbursement setback would materially affect revenue.

Scope
Commercial revenue concentration
Materiality
high
high

Clinical and regulatory failure of pipeline assets

Casdozokitug, CHS-114, and other candidates are still in development and may never reach approval.

Scope
Pipeline development
Materiality
high
high

Competitive pressure in immuno-oncology

LOQTORZI competes with entrenched PD-1/PD-L1 therapies from much larger companies with stronger commercial resources.

Scope
Market share and pricing
Materiality
high
high

Payer and pricing pressure

Coverage, formulary placement, and state/federal drug pricing rules can limit access and net pricing.

Scope
U.S. reimbursement
Materiality
high
medium

Manufacturing and supply chain reliance

The company relies on CMOs for commercial and clinical supply, which can create delays, quality issues, or cost inflation.

Scope
Third-party production
Materiality
medium
Product sales discounts and allowances
Can materially change reported product revenue and margins
Collaboration royalties and milestones
Affects gross margin and operating cash requirements
Discontinued operations
Can distort trend analysis across years
Fair value measurements
Can introduce earnings volatility unrelated to core operations

Citius Pharmaceuticals, Inc.

CTXR · Pharmaceutical Preparations

Lantheus Holdings, Inc.

LNTH · In Vitro & In Vivo Diagnostic Substances

CITIUS ONCOLOGY, INC.

CTOR · Pharmaceutical Preparations

Assertio Holdings, Inc.

Pharmaceutical Preparations

CG Oncology, Inc.

CGON · Biological Products, (No Diagnostic Substances)

Corvus Pharmaceuticals, Inc.

CRVS · Pharmaceutical Preparations

: 28.4.2026